Obstructive Sleep Apnea Linked with Higher Risk of Gout
August 31, 2018 (Investorideas.com Newswire) New research reveals that people with obstructive sleep apnea (OSA) have a higher risk of developing gout, even beyond the first years after being diagnosed with the sleep disorder. The findings are published in Arthritis & Rheumatology, an official journal of the American College of Rheumatology.
OSA is associated with a range of serious comorbidities, and it has previously been shown that people with OSA have a higher risk of developing gout in the first year after diagnosis. To investigate whether they may also be more likely to develop gout over a longer term, a team led by Edward Roddy, DM and Milica Blagojevic-Bucknall, PhD, of Keele University in the UK, examined information on 15,879 patients with OSA and 63,296 without, with a median follow-up of 5.8 years.
During follow-up. 4.9% of OSA and 2.6% of non-OSA patients developed gout. Incidence rates per 1000 person-years were 7.83 and 4.03 among those with and without OSA, respectively, for a 42% increased risk among OSA patients. (A person-year is the number of years of follow-up multiplied by the number of people in the analysis.)
An elevated risk of developing gout was observed throughout follow-up for OSA patients, but it was highest one to two years after diagnosis of OSA. This finding was seen in patients with normal body mass index as well as those who were overweight or obese; however, the risk was greater in those with normal weight.
"People with sleep apnoea are at an increased risk of gout in both the short and long term. Since this risk was highest in people with normal body mass index, doctors and other health professionals should consider the possibility of gout in patents with sleep apnoea regardless of body mass index," said Dr. Roddy.
It's thought that intermittent oxygen deficiency due to OSA leads to over- production of uric acid, which causes gout. "Sleep apnea is commonly treated with continuous positive airways pressure-or CPAP-therapy. Since CPAP treatment corrects low oxygen levels it might also be expected to reduce uric acid levels, which could possibly reduce the risk of developing gout or treat existing gout; however, further research is needed to investigate the effect of treatment with CPAP in people with gout," said Dr. Blagojevic-Bucknall.
The information contained in this release is protected by copyright. Members of the media may sign up for embargoed news or to request a copy of any study please contact:
Dawn Peters (US) +1 781-388-8408
Follow us on Twitter @WileyNews
"Gout as a consequence of obstructive sleep apnea: a matched cohort study." Milica Blagojevic-Bucknall, Christian Mallen, Sara Muller, Richard Hayward, Sophie West, Hyon Choi, and Edward Roddy. Arthritis & Rheumatology; Published Online: August 30, 2018 (DOI: 10.1002/art.40662).
URL Upon Publication: http://doi.wiley.com/10.1002/art.40662
About the Journal
Arthritis & Rheumatology is an official journal of the American College of Rheumatology (ACR) and covers all aspects of inflammatory disease. The American College of Rheumatology (www.rheumatology.org) is the professional organization whose members share a dedication to healing, preventing disability, and curing the more than 100 types of arthritis and related disabling and sometimes fatal disorders of the joints, muscles, and bones. Members include practicing physicians, research scientists, nurses, physical and occupational therapists, psychologists, and social workers. The journal is published by Wiley on behalf of the ACR. For more information, please visit http://wileyonlinelibrary.com/journal/art.
Wiley is a global leader in education and scholarly research. Our online scientific, technical, medical, and scholarly journals, combined with our digital learning, assessment and certification solutions help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 210 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at www.wiley.com.
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release on the Investorideas.com newswire https://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.